NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

新型冠狀病毒感染疾病 (COVID-19) 檢驗的全球市場,最新版 (2021年):分子、抗原檢驗市場,治療,突然變異,家庭檢驗,其他趨勢

COVID-19 Testing Market Update 2021: Molecular & Antigen Markets, Procedures, Mutations, Home Tests, and Other Trends

出版商 Kalorama Information 商品編碼 1006562
出版日期 內容資訊 英文 72 Pages
商品交期: 最快1-2個工作天內
價格
新型冠狀病毒感染疾病 (COVID-19) 檢驗的全球市場,最新版 (2021年):分子、抗原檢驗市場,治療,突然變異,家庭檢驗,其他趨勢 COVID-19 Testing Market Update 2021: Molecular & Antigen Markets, Procedures, Mutations, Home Tests, and Other Trends
出版日期: 2021年02月16日內容資訊: 英文 72 Pages
簡介

經過新型冠狀病毒感染疾病 (COVID-19)的感染擴大的不幸的一年,全球診斷產業恆久性大幅改變。為了查出病毒的存在和免疫應答雙方,有幾百項檢驗產品於市場上市。還有體外診斷市場擴大數十億美元份。企業將焦點轉向感染疾病對策,加上新產品上市,推動增產和企業收購,擴大收益2∼3倍。

COVID-19檢驗產品的市場:分子、抗原、抗體檢驗 (共380億美元份)

本報告提供全球新型冠狀病毒感染疾病 (COVID-19) 用各種檢驗的市場相關分析,疾病概要和市場基本結構,背景情況和主要的影響要素,主要的檢驗藥的開發、上市情形,市場規模趨勢預測 (2020年∼2021年),各地區的詳細趨勢 (北美、歐洲、亞洲等),主要供應商的簡介等調查。

目錄

第1章 摘要整理

第2章 概要,已上市檢驗產品,供應商趨勢

  • 突然變異
  • 家庭檢驗
  • 疫苗
  • 由於COVID-19的PoC (照護現場) 利用的加速化
    • mPOC (PoC分子診斷)
  • 其他趨勢
    • WHO (世界衛生組織)
    • 蛋白質生物感應器
    • COVID-19檢驗的最近的供應商趨勢
    • 急救診療所和COVID-19

第3章 已上市檢驗產品

  • 分子檢驗
  • 抗原檢驗
  • 抗體檢驗

第4章 新型冠狀病毒感染疾病 (COVID-19) 檢驗的市場

  • 分子檢驗市場
  • 未來預測
  • 各地區的明細
  • 抗原檢驗市場
  • 未來預測
  • 各地區的明細

分析對象企業 (部分)

  • Roche
  • Abbott
  • Quidel
  • Becton Dickinson
  • Bio-Rad
  • Hologic
  • Thermo Fisher
  • Ellume
  • Qiagen
  • Seegene
  • GenMark
  • Quest
  • LabCorp
  • OraSure
  • Agilent/Dako
  • Visby
  • Illumina
  • Cue Health
  • Sherlock Biosciences
目錄
Product Code: 21-018

As the unfortunate milestone of one full year of the global COVID-19 pandemic worldwide is reached, the diagnostic industry has been changed, perhaps permanently. Hundreds of test products are on the market to detect the virus, both for its presence and immune response. And billions of dollars have been added to the in vitro diagnostic market. Companies have doubled and tripled revenues, bought new companies, increased manufacturing, shifted focus to infectious diseases and launched new products.

"A 38 Billion Dollar Market for COVID-19 Test Products: Molecular, Antigen, and Antibody Tests."

New features have been added to tests, such us variant and mutation detection, combination with flu and RSV, more specific [neutralizing] antibody detection, or ultra-large volume capacities. A new category of testing has been crated than in a year is rivaling all others in volume. And with it, market changes a shift of top categories in IVD towards infectious disease testing and other COVID-19 related tests. This report, COVID-19 Testing Update 2021, provides the most current analyst assessment of the market for COVID-19 testing. As part of its report data, the report includes:

  • Overview of disease progress, trends, developments
  • Mutations: What to Expect
  • The Arrival and Potential of Home Testing
  • Markets for COVID-19 Antigen Tests, 2020 and 2021
  • Markets for COVID-19 Molecular Test, 2020 and 2021
  • Markets for COVID-19 Antibody Tests, 2020 and 2021
  • Markets by Geography (US, Europe, Asia, ROW)
  • Antigen Products on the Market
  • PCR and Other Molecular Products on the Market
  • Vaccine Impact on Market
  • FDA Emergency Authorized Tests: Molecular, Antigen and Antibody
  • Leading Vendors

New companies have entered the diagnostics market sensing opportunities and to contribute to the emergency need. And some companies have grown and make expansions and acquisitions. Kalorama looks at these companies and also the major IVD players and how COVID-19 has affected their performance.

MAJOR TRENDS

  • Mutations
  • Vaccines
  • COVID-19 Endemic ?
  • Home Testing
  • Biden Admin. Actions
  • IVD Revenues Boom
  • New Market Entrants

Key Trends Examined in the Report:

This is an important time to look at this market as several trends that could change the direction of diagnostic take hold:

  • Biden Administration Plans - Already billions of dollars in spending are, and laboratory associations are asking for more. What impact will this have no test markets.
  • Home Testing - Once a rarely thought of possibility in major IVD markets [outside of glucose, ovulation and a few infectious tests of low volume], COVID-19 has brought the idea of testing at home to reality, and manufacturers are developing systems and considering plans that may extend beyond this disease alone. Government financing is fueling this trend as well.
  • Mutations - changes to SARS-COV-2 may change the diagnostic response. We examine that in a special section on variants and mutations. COVID-19 like any virus has some variants and mutations. These can affect testing results in various way. Currently there is no widespread emergency necessitating changes in major tests. But of note is that the U.S. is setting up protocols. On Monday, February 22, 2021 the FDA issued new guidance for SARS-CoV-2 test developers. The agency made it clear they are to consider the impact of mutations on their tests using sequencing to determine any impact.
  • Vaccines - As millions are vaccinated, where does that leave testing companies. IVD companies have weighed in, and we review their predictions and assess the impact vaccines have had on testing markets for other conditions such as cervical cancer and influenza.
  • Endemic Status - There are increasing predictions of a possible endemic status of COVID-19. That is to say, a disease with recurring outbreaks in humans. After all the endemic betacoronavirus that causes mild respiratory illness generally sees immunity last only a year.
  • Supply Shortages -The global pandemic demonstrated that molecular testing methods have particular supply needs that can be challenged in large-scale use. Supply shortages have plagued the U.S. response to COVID-19 testing, and the federal government is open to new ideas for solutions. The former head of COVID-19 testing response described the U.S. supply chain at the start of the pandemic as a "wreck." What are the implications for future testing?
  • Larger Test Volumes - As with society generally, some of the changes that have swept over lab medicine in the last year are likely to be lasting, regardless of how quickly the pandemic gets under control. This report looks at the trends in COVID-19 as they stand currently, with market estimates for 2020 and forecast for 2021 with a variety of formats.

Companies Adjust to COVID-19

Just in the last two months, COVID-19 has affected considerable change at diagnostic companies. One comapny has acquisitions, fortified with cash from increased sales of test kits. Others launched home testing kits. One cash-negative company was made cash-postive, while another doubled its test capacity and yet another tripled sales of instruments. Companies not in infectious disease testing are quickly pivoting to it. The first test for asymptomatic patients was approved, and new innovative features such as saliva sampling or ultra-high throughput even CRISPR are being added to tests.

Companies mentioned in the report include:

  • Roche
  • Abbott
  • Quidel
  • Becton Dickinson
  • Bio-Rad
  • Hologic
  • Thermo Fisher
  • Ellume
  • Qiagen
  • Seegene
  • GenMark
  • Quest
  • LabCorp
  • OraSure
  • Agilent/Dako
  • Visby
  • Illumina
  • Cue Health
  • Sherlock Biosciences

As well as many other companies.

TABLE OF CONTENTS

CHAPTER ONE: EXECUTIVE SUMMARY

  • OVERVIEW
  • SCOPE AND METHODOLOGY
  • MARKET OVERVIEW AND POTENTIAL
  • A YEAR OF COVID-19
  • TEST EUAs
    • Antigen Tests Arrive
  • SIZE AND GROWTH OF MARKET
  • RECENT DEVELOPMENTS

CHAPTER TWO: OVERVIEW, TESTS ON THE MARKET, VENDOR DEVELOPMENTS

  • MUTATIONS
  • HOME TESTING
  • VACCINES
  • COVID-19 ACCELERATING POC USAGE
    • mPOC
  • OTHER TRENDS
    • WHO
    • Protein biosensors
    • RECENT VENDOR DEVELOPMENTS IN COVID-19 TESTING
    • Urgent Care and COVID-19

CHAPTER THREE: TESTS ON THE MARKET

  • Molecular
  • Antigen
  • Antibody

CHAPTER FOUR: COVID-19 TESTING MARKET

  • MOLECULAR TEST MARKET
  • Forecast
  • Geographic Breakout
  • ANTIGEN TEST MARKET
  • Forecast
  • Geographic Breakout